SEC filing record
Primary Source · SEC.gov

CND Life Sciences, Inc.

2026 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalOffering upsizedForm D/A · 2026-08-0312 events: 3 offering upsized, 3 sold increased, 3 investors increasedLast filing 2026-08-03

Raised

$6M

Investors

14

Min Invest

$25,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

CND Life Sciences, Inc. is a Delaware corporation that first filed a Form D on January 20, 2021 and most recently amended it on August 3, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers debt. CND Life Sciences, Inc. reported $6,316,514 sold from 14 investors of a $6,316,514 total offering as of the Form D filed August 3, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $25,000. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 9165 E. Del Camino Drive, Suite 101, Scottsdale, AZ 85258-4381.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001841099
Entity NameCND Life Sciences, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address9165 E. Del Camino Drive, Suite 101, Scottsdale, AZ 85258-4381
Phone(617) 223-1585
Industry / Fund TypeBiotechnology
Securities TypeDebt
First Sale DateJune 9, 2026
Filing DateAugust 3, 2026
Accession Number0001841099-26-000002
Total Offering Amount$6,316,514
Total Amount Sold$6,316,514
Amount Remaining$0
Total Investors14
Non-Accredited InvestorsNone
Minimum Investment$25,000
Offering DurationOne year or less
Revenue RangeDecline to Disclose
State (Issuer Address)AZ
Amendment Count12 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

12

latest Aug 3, 2026

Critical / warning

0 / 0

2 watch · 10 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

7

closed, lapsed

Latest event Sold increase · Aug 3, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 12 filing events with values and deltas, latest 2026-08-03, and alerts on the next one
  • 7 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Richard J. Morello

Executive Officer, Director · Atlanta, GA

Todd Levine

Executive Officer, Director · Paradise Valley, AZ

Peter Harris

Executive Officer, Director · Brookline, MA

Enrique Carrazana

Director · Coral Gables, FL

Christopher Gibbons

Director · Brookline, MA

Jack Seaver

Director · New York, NY

Questions About CND Life Sciences, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is CND Life Sciences, Inc.?

CND Life Sciences, Inc. is a Delaware corporation that filed a Form D with the SEC on August 3, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of debt.

Is CND Life Sciences, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. CND Life Sciences, Inc. filed a Form D with the SEC on August 3, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $6,316,514 sold to 14 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is CND Life Sciences, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that CND Life Sciences, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has CND Life Sciences, Inc. raised?

CND Life Sciences, Inc. reported $6,316,514 sold from 14 investors of a $6,316,514 total offering as of the Form D filed August 3, 2026.

Who can invest in CND Life Sciences, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $25,000.

What is the minimum investment in CND Life Sciences, Inc.?

The Form D lists $25,000 as the minimum investment accepted from any outside investor as of August 3, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling CND Life Sciences, Inc. and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.

Who is behind CND Life Sciences, Inc.?

The Form D lists 6 related persons: Richard J. Morello, executive officer, director; Todd Levine, executive officer, director; Peter Harris, executive officer, director; Enrique Carrazana, director; Christopher Gibbons, director; Jack Seaver, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is CND Life Sciences, Inc. located?

The issuer's address on its SEC filings is 9165 E. Del Camino Drive, Suite 101, Scottsdale, AZ 85258-4381. Its phone number of record is 617-223-1585. It is organized under the laws of Delaware.

How long is the CND Life Sciences, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 5 amendments are on record for this CIK.

What is CND Life Sciences, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.